Neumora Therapeutics, Inc. Common StockNMRANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank60
3Y CAGR+19.2%
5Y CAGR+15.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+19.2%/yr
Annual compound
5Y CAGR
+15.3%/yr
Recent acceleration
Percentile
P60
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $177.31M | -11.8% |
| 2024 | $200.93M | +40.8% |
| 2023 | $142.72M | +36.2% |
| 2022 | $104.75M | -50.8% |
| 2021 | $212.78M | +144.2% |
| 2020 | $87.13M | - |